Clinical Trial

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-15; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Recruiting 2024-12-16
Trial Details
NCT Number NCT06510361
Lead Sponsor Beth Israel Deaconess Medical Center
Collaborators: Genmab
Conditions Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
Enrollment 35 participants
Start Date 2024-11-20
Primary Completion 2026-05-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-13